Cargando…

Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: A meta-analysis

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma (NHL), representing 30% of all lymphoma cases. Within the first 2-3 years following immunochemotherapy, 30-40% of patients will experience a relapse or a refractory disease, thereby exhibiting a poor prog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Mansour, Mubarak, Al-Foheidi, Meteb, Ibrahim, Ezzeldin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416618/ https://www.ncbi.nlm.nih.gov/pubmed/32789017 http://dx.doi.org/10.3892/mco.2020.2103

Ejemplares similares

Energy and caloric restriction, and fasting and cancer: a narrative review
por: Ibrahim, Ezzeldin M., et al.
Publicado: (2020)

Risk of second breast cancer in female Hodgkin’s lymphoma survivors: a meta-analysis
por: Ibrahim, Ezzeldin M, et al.
Publicado: (2012)

The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
por: Albanyan, Omar, et al.
Publicado: (2022)

Granulocyte Colony Stimulating Factor (G-CSF) Induced Splenic Infarction in Breast Cancer Patient Treated with Dose-Dense Chemotherapy Regimen
por: Alshamrani, Majed A., et al.
Publicado: (2019)

Diffuse Large B-Cell Lymphoma: Saudi Lymphoma Group's Clinical Practice Guidelines for Diagnosis, Management and Follow-up
por: Al-Mansour, Mubarak, et al.
Publicado: (2019)

CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope
por: Hopfinger, Georg, et al.
Publicado: (2019)

Characteristics of premanufacture CD8(+) T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma
por: Wang, Yao, et al.
Publicado: (2023)

Combination of palbociclib with adjuvant endocrine therapy for treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer: An experience at two cancer centers in Saudi Arabia
por: Al-Foheidi, Meteb H., et al.
Publicado: (2022)

CD19 directed CAR T cell therapy in diffuse large B-cell lymphoma
por: Quintás-Cardama, Alfonso
Publicado: (2018)

Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma
por: Al-Mansour, Mubarak M., et al.
Publicado: (2018)

Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma
por: Castaneda-Puglianini, Omar, et al.
Publicado: (2021)

Lymphoma immunotherapy: Efficacy, safety and accessibility to CAR-T therapy for lymphomas
por: Borchmann, Peter
Publicado: (2018)

Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
por: Porpaczy, Edit, et al.
Publicado: (2021)

Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era
por: Atallah-Yunes, Suheil Albert, et al.
Publicado: (2022)

CAR T-Cell Therapy for Large B-Cell Lymphoma
por: Alencar, Maritza C.
Publicado: (2019)

CAR-T Cell Therapy in Large B Cell Lymphoma
por: Testa, Ugo, et al.
Publicado: (2023)

Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma
por: Zundler, Sebastian, et al.
Publicado: (2023)

The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma
por: Palmieri, R., et al.
Publicado: (2019)

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-cell Lymphoma in the Era of CAR-T Cell Therapy
por: Lekakis, Lazaros J., et al.
Publicado: (2019)

Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma
por: Maldonado-Pérez, Noelia, et al.
Publicado: (2022)

Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer.
por: Paillassa, Jérôme, et al.
Publicado: (2021)

Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma
por: Wudhikarn, Kitsada, et al.
Publicado: (2020)

Regional Injection of CAR-T Cells for the Treatment of Refractory and Recurrent Diffuse Large B Cell Lymphoma: A Case Report
por: Wei, Yan-Hui, et al.
Publicado: (2020)

P1398: AXICABTAGENE CILOLEUCEL VERSUS TISAGENLECLEUCEL CAR-T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Gagelmann, Nico, et al.
Publicado: (2023)

Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma
por: Goto, Hideki, et al.
Publicado: (2020)

The Outcomes of Diffuse Large B-cell Lymphoma Patients with Synchronous and Early Central Nervous System Involvement: A Single-Center Experience
por: Al-Mansour, Mubarak, et al.
Publicado: (2023)

Diffuse Large B-Cell Lymphoma Mimicking an Ulcerative Colitis Flare
por: Mansour, Ramy, et al.
Publicado: (2019)

Primary Mediastinal Large B-Cell Lymphoma: Saudi Lymphoma Group's Clinical Practice Guidelines for Diagnosis, Management and Follow-up
por: Alhejazi, Ayman, et al.
Publicado: (2019)

Diffuse Large B-Cell Breast Lymphoma: A Case Series
por: Al Battah, Afaf H, et al.
Publicado: (2017)

Engineering CAR T cells for enhanced efficacy and safety
por: Wu, Yiqian, et al.
Publicado: (2022)

Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma
por: Panjwani, M. Kazim, et al.
Publicado: (2019)

CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Progressive Muscular Dystrophy: A Case Report
por: Chen, Liting, et al.
Publicado: (2022)

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
por: Bachy, Emmanuel, et al.
Publicado: (2022)

Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany
por: Skalt, Daniela, et al.
Publicado: (2022)

Outcome of Patients with Diffuse Large B-Cell Lymphoma Relapsing after Autologous Transplant before Availability of CAR-T Cell Treatment
por: von Matt, Stefanie, et al.
Publicado: (2023)

A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma
por: Shouse, Geoffrey, et al.
Publicado: (2023)

Breast Cancer Patients’ Perceptions of Their Experience With Chemotherapy-Induced Nausea and Vomiting and Its Impact on Quality of Life in Jeddah, Saudi Arabia
por: Ilyas, Ahmed B, et al.
Publicado: (2020)

Limited efficacy of pixantrone in refractory diffuse large B-cell lymphoma
por: Novakovic, Aleksander, et al.
Publicado: (2020)

The Application of the Lymphoma International Prognostic Index to Predict Venous Thromboembolic Events in Diffuse Large B-Cell Lymphoma Patients
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b736ogns7mgbciqlg50bmccell